Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fezolinetant

FDA-approved product (tablet, oral), marketed as Veozah.

Registered studies
32
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fezolinetant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hot flashes

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other gynecologicals
FDA pharmacologic class
Neurokinin 3 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

32registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fezolinetant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fezolinetant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause

    NCT06206408 · start 2024-02-16

    Registered record
    Registry ID
    NCT06206408
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-02-16
    Completion
    2025-12-18
    Enrolment
    410

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

    NCT06049797 · start 2023-11-15

    Registered record
    Registry ID
    NCT06049797
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant; Paroxetine; Citalopram; Escitalopram; Desvenlafaxine; Venlafaxine; Gabapentin; Clonidine; Pregabalin; Oxybutynin; Any other SSRI/SNRI not already specified; Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-11-15
    Completion
    2026-05-07
    Enrolment
    999

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant; Paroxetine; Citalopram; Escitalopram +8 more
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

    NCT05034042 · start 2021-11-17

    Registered record
    Registry ID
    NCT05034042
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-11-17
    Completion
    2022-12-23
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

    NCT05033886 · start 2021-11-08

    Registered record
    Registry ID
    NCT05033886
    Conditions
    Vasomotor Symptoms
    Interventions
    fezolinetant; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-11-08
    Completion
    2023-04-20
    Enrolment
    453

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasomotor Symptoms
    Interventionfezolinetant; placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects

    NCT04793204 · start 2021-03-24

    Registered record
    Registry ID
    NCT04793204
    Conditions
    Healthy Volunteers
    Interventions
    fezolinetant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-24
    Completion
    2021-05-21
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Interventionfezolinetant
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants

    NCT04641260 · start 2020-11-20

    Registered record
    Registry ID
    NCT04641260
    Conditions
    Healthy Subjects
    Interventions
    Fezolinetant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-11-20
    Completion
    2021-02-21
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionFezolinetant
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function

    NCT04482270 · start 2020-09-02

    Registered record
    Registry ID
    NCT04482270
    Conditions
    Hepatic Impairment; Healthy Volunteers
    Interventions
    fezolinetant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-09-02
    Completion
    2021-03-22
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment; Healthy Volunteers
    Interventionfezolinetant
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

    NCT04476849 · start 2020-08-10

    Registered record
    Registry ID
    NCT04476849
    Conditions
    Healthy Volunteers; Renal Impairment
    Interventions
    fezolinetant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-08-10
    Completion
    2022-03-11
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers; Renal Impairment
    Interventionfezolinetant
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause

    NCT04451226 · start 2020-07-30

    Registered record
    Registry ID
    NCT04451226
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-07-30
    Completion
    2022-06-13
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant
    PhasePhase 3
    Registry statusCompleted

  • A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause

    NCT04234204 · start 2020-03-17

    Registered record
    Registry ID
    NCT04234204
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-03-17
    Completion
    2022-04-20
    Enrolment
    302

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

    NCT04277624 · start 2020-02-20

    Registered record
    Registry ID
    NCT04277624
    Conditions
    Healthy Volunteers
    Interventions
    fezolinetant - test formulation; fezolinetant - reference formulation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-02-20
    Completion
    2021-02-26
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Interventionfezolinetant - test formulation; fezolinetant - reference formulation
    PhasePhase 1
    Registry statusCompleted

  • A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

    NCT04003155 · start 2019-07-11

    Registered record
    Registry ID
    NCT04003155
    Conditions
    Hot Flashes
    Interventions
    fezolinetant; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-07-11
    Completion
    2021-08-11
    Enrolment
    527

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    Interventionfezolinetant; placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

    NCT04003142 · start 2019-07-10

    Registered record
    Registry ID
    NCT04003142
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-07-10
    Completion
    2021-04-23
    Enrolment
    501

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant; placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

    NCT04003389 · start 2019-07-10

    Registered record
    Registry ID
    NCT04003389
    Conditions
    Hot Flashes
    Interventions
    fezolinetant; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-07-10
    Completion
    2022-01-04
    Enrolment
    1,831

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    Interventionfezolinetant; placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects

    NCT03436849 · start 2018-02-22

    Registered record
    Registry ID
    NCT03436849
    Conditions
    Healthy Subjects
    Interventions
    ESN364; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-02-22
    Completion
    2018-05-23
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionESN364; Placebo
    PhasePhase 1
    Registry statusCompleted